Cargando…
Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy
AIM: Skeletal muscle volume has been reported to be an important factor that determines overall survival (OS) and post‐progression survival (PPS) in patients with hepatocellular carcinoma (HCC). However, the impact of skeletal muscle volume on HCC with Barcelona Clinic Liver Cancer (BCLC) stage B (B...
Autores principales: | Saeki, Issei, Yamasaki, Takahiro, Yamauchi, Yurika, Kawaoka, Tomokazu, Uchikawa, Shinsuke, Hiramatsu, Akira, Aikata, Hiroshi, Kobayashi, Kazufumi, Kondo, Takayuki, Ogasawara, Sadahisa, Chiba, Tetsuhiro, Kawano, Reo, Chayama, Kazuaki, Kato, Naoya, Takami, Taro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225214/ https://www.ncbi.nlm.nih.gov/pubmed/36951579 http://dx.doi.org/10.1002/cam4.5810 |
Ejemplares similares
-
Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma
por: Saeki, Issei, et al.
Publicado: (2021) -
Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment
por: Yamasaki, Takahiro, et al.
Publicado: (2022) -
Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib
por: Yamaoka, Kenji, et al.
Publicado: (2021) -
Early experience of seven hepatocellular carcinoma cases treated with regorafenib
por: Uchikawa, Shinsuke, et al.
Publicado: (2018) -
Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy
por: Ohya, Kazuki, et al.
Publicado: (2019)